EGPA, previously known as Churg-Strauss syndrome, is a rare inflammatory disorder characterized by asthma, necrotizing ...

Neuralink has proven its electronics to brain connection device and now has FDA approval for a Blindsight device.

The FDA approved benralizumab (Fasenra) for adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

Elon Musk's Blindsight brain implant has achieved a major milestone. It's now being worn by Geordi La Forge. No wait, it's ...

Theratechnologies’ supply hiccup is the second caused by third-party manufacturing problems in less than a week. On Friday, ...

Elon Musk’s Neuralink has recently achieved a significant milestone with its experimental vision-restoring implant, ...

The pitch sounds a bit sci-fi: a helmet called Lily that people undergoing chemotherapy wear to prevent the hair loss, which ...

The FDA’s clearance could double Kisqali’s breast cancer market. Elsewhere, Novo is exploring new ways to deliver genetic therapies and Bain is funding a growing CDMO.

ICT01 showed tolerable safety and promising clinical activity as a monotherapy and is now being investigated in combination ...

Investors are optimistic that small- and mid-cap stocks will rally this year after a tough 2023, as attention shifts from the ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated with ...

If you’re due for a mammogram, expect a more in-depth report. Last week, the FDA ruled that women across the United States will get a report with their mammogram ...